We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-5.09%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$220M
AUM Growth
+$28.5M
Cap. Flow
+$38.3M
Cap. Flow %
17.42%
Top 10 Hldgs %
81.25%
Holding
35
New
9
Increased
14
Reduced
7
Closed
4

Top Buys

1
AMYT
Amryt Pharma plc American Depositary Shares
AMYT
+$33.9M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$14.5M
3
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$6.4M
4
ADMS
Adamas Pharmaceuticals
ADMS
+$5.93M
5
OVID icon
Ovid Therapeutics
OVID
+$4.57M

Top Sells

1
CHMA
Chiasma, Inc. Common Stock
CHMA
+$32M
2
CFMS
Conformis, Inc. Common Stock
CFMS
+$8.66M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$3.27M
4
XOMA
Xoma
XOMA
+$2.84M
5
EYPT icon
EyePoint Inc
EYPT
+$2.13M

Sector Composition

1 Healthcare 90.44%
2 Financials 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMYT
1
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$69.9M 31.8%
5,801,748
+3,004,004
+107% +$33.9M
CTIC
2
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$23.5M 10.69%
7,964,329
+331,799
+4% +$904K
ADMS
3
DELISTED
Adamas Pharmaceuticals
ADMS
$19.2M 8.75%
3,914,938
+1,220,643
+45% +$5.93M
LKFT
4
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$12.8M 5.85%
+244,205
New +$14.5M
OVID icon
5
Ovid Therapeutics
OVID
$455M
$10.9M 4.97%
3,252,892
+1,252,892
+63% +$4.57M
GYRE icon
6
Gyre Therapeutics
GYRE
$675M
$10.8M 4.93%
351,335
-58,848
-14% -$1.94M
SBBP
7
DELISTED
Strongbridge Biopharma plc.
SBBP
$9.16M 4.17%
4,489,687
+1,184,070
+36% +$2.76M
APEN
8
DELISTED
Apollo Endosurgery, Inc.
APEN
$8.26M 3.76%
912,125
+149,942
+20% +$1.29M
AFMD
9
DELISTED
Affimed
AFMD
$7.18M 3.27%
116,147
+31,147
+37% +$2.05M
GMDA
10
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$6.76M 3.08%
1,724,201
+1,280,694
+289% +$6.4M
XGN icon
11
Exagen
XGN
$106M
$5.31M 2.42%
390,637
+221,095
+130% +$2.94M
CELC icon
12
Celcuity
CELC
$4.31B
$5.3M 2.41%
294,692
+75,741
+35% +$1.61M
KA
13
DELISTED
Kineta, Inc. Common Stock
KA
$4.97M 2.26%
68,813
+5,676
+9% +$402K
ATYR
14
aTyr Pharma
ATYR
$50M
$3.73M 1.7%
+410,535
New +$2.46M
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$3.49M 1.59%
200,000
– –
SYBX
16
DELISTED
Synlogic
SYBX
$3.05M 1.39%
+66,667
New +$3.11M
ELTX icon
17
Elicio Therapeutics
ELTX
$81.7M
$2.74M 1.25%
28,018
+5,734
+26% +$620K
EOLS icon
18
Evolus
EOLS
$377M
$2.29M 1.04%
+300,000
New +$3.1M
AVTX icon
19
Avalo Therapeutics
AVTX
$1.02B
$1.85M 0.84%
+295
New +$2.39M
CDTX
20
DELISTED
Cidara Therapeutics
CDTX
$1.75M 0.8%
39,141
-21,423
-35% -$814K
XOMA
21
DELISTED
Xoma
XOMA
$1.7M 0.77%
68,542
-96,499
-58% -$2.84M
CYPH
22
Cypherpunk Technologies Inc
CYPH
$75.4M
$1M 0.46%
+25,000
New +$470K
ATRS
23
DELISTED
Antares Pharma, Inc.
ATRS
$961K 0.44%
+264,100
New +$1.07M
EYPT icon
24
EyePoint Inc
EYPT
$1.12B
$839K 0.38%
80,537
-223,314
-73% -$2.13M
DMAC icon
25
DiaMedica Therapeutics
DMAC
$393M
$665K 0.3%
165,775
-254,167
-61% -$973K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Stonepine Capital Management held 35 positions worth $220M, up 15% from $191M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Stonepine Capital Management deployed $38.3M of net new capital in Q3 2021, opening 9 new positions and adding to 14 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 244,205 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Conformis, Inc. Common Stock, an estimated $8.66M trimmed.

  • Stonepine Capital Management's largest Q3 2021 buy was Lakefront Biotherapeutics American Depositary Shares: 244,205 shares worth $12.8M.
  • Stonepine Capital Management added most to Amryt Pharma plc American Depositary Shares in Q3 2021, an estimated $33.9M increase.
  • Stonepine Capital Management's biggest Q3 2021 reduction was Conformis, Inc. Common Stock, cutting an estimated $8.66M.
  • Stonepine Capital Management fully exited Chiasma, Inc. Common Stock in Q3 2021, selling an estimated $32M.
  • Stonepine Capital Management's ten largest holdings make up 81% of its $220M portfolio in Q3 2021.
  • Stonepine Capital Management opened 9 new positions and closed 4 in Q3 2021.
  • Stonepine Capital Management's portfolio value rose 15% quarter-over-quarter to $220M.

Based on Stonepine Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.